(BTSG) BrightSpring Health - Ratings and Ratios
Pharmacy,Rehabilitation,Nursing,Infused,Behavioral
BTSG EPS (Earnings per Share)
BTSG Revenue
Description: BTSG BrightSpring Health
BrightSpring Health Services, Inc. is a healthcare services platform operating in the United States, providing home and community-based services through its two segments: Pharmacy Solutions and Provider Services. The company delivers pharmacy and provider services, including clinical and supportive care, to Medicare, Medicaid, and insured populations.
To further analyze the companys performance, we can examine key performance indicators (KPIs) such as revenue growth, operating margins, and patient satisfaction. BrightSpring Health Services, Inc. has likely experienced growth in revenue due to the increasing demand for home and community-based healthcare services. The companys operating margins may be influenced by its ability to manage costs and optimize its services. Additionally, patient satisfaction is a crucial KPI in the healthcare industry, and BrightSpring Health Services, Inc. may focus on delivering high-quality care to achieve high patient satisfaction ratings.
From a financial perspective, BrightSpring Health Services, Inc.s market capitalization is approximately $3.53 billion, indicating a significant presence in the healthcare services industry. The companys price-to-earnings (P/E) ratio is 74.44, which may suggest that the stock is overvalued. However, the forward P/E ratio is 25.91, indicating potential for future earnings growth. The return on equity (RoE) is 3.50, which may be considered relatively low, suggesting that the company may not be generating sufficient returns on shareholder equity.
To evaluate the stocks potential, we can also consider its support and resistance levels. The stock has support levels at $18.7, $18.0, $17.0, and $14.9, indicating potential buying opportunities. Resistance levels are at $21.4 and $24.1, suggesting potential selling pressure. By analyzing these levels, investors can make informed decisions about buying or selling the stock.
BTSG Stock Overview
| Market Cap in USD | 4,958m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2024-01-26 |
BTSG Stock Ratings
| Growth Rating | 90.0% |
| Fundamental | 56.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 58.2% |
| Analyst Rating | 4.67 of 5 |
BTSG Dividends
Currently no dividends paidBTSG Growth Ratios
| Growth Correlation 3m | 50.7% |
| Growth Correlation 12m | 72.1% |
| Growth Correlation 5y | 91.8% |
| CAGR 5y | 71.93% |
| CAGR/Max DD 3y | 2.02 |
| CAGR/Mean DD 3y | 10.59 |
| Sharpe Ratio 12m | 0.56 |
| Alpha | 80.05 |
| Beta | 0.624 |
| Volatility | 58.13% |
| Current Volume | 4179.1k |
| Average Volume 20d | 1935.8k |
| Stop Loss | 25.3 (-4.3%) |
| Signal | 0.51 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (65.5m TTM) > 0 and > 6% of Revenue (6% = 719.1m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 0.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.53% (prev 3.91%; Δ 5.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 268.5m > Net Income 65.5m (YES >=105%, WARN >=100%) |
| Net Debt (2.64b) to EBITDA (424.7m) ratio: 6.22 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (216.3m) change vs 12m ago 26.22% (target <= -2.0% for YES) |
| Gross Margin 12.88% (prev 12.38%; Δ 0.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 207.6% (prev 172.1%; Δ 35.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.23 (EBITDA TTM 424.7m / Interest Expense TTM 191.5m) >= 6 (WARN >= 3) |
Altman Z'' 1.40
| (A) 0.19 = (Total Current Assets 2.65b - Total Current Liabilities 1.51b) / Total Assets 5.94b |
| (B) -0.03 = Retained Earnings (Balance) -164.4m / Total Assets 5.94b |
| (C) 0.04 = EBIT TTM 235.2m / Avg Total Assets 5.77b |
| (D) -0.04 = Book Value of Equity -167.0m / Total Liabilities 4.20b |
| Total Rating: 1.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 56.60
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 2.56% = 1.28 |
| 3. FCF Margin 1.59% = 0.40 |
| 4. Debt/Equity 1.48 = 1.50 |
| 5. Debt/Ebitda 6.05 = -2.50 |
| 6. ROIC - WACC -1.10% = -1.37 |
| 7. RoE 3.92% = 0.33 |
| 8. Rev. Trend 96.72% = 4.84 |
| 9. Rev. CAGR 18.33% = 2.29 |
| 10. EPS Trend 53.67% = 1.34 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BTSG shares?
Over the past week, the price has changed by +9.61%, over one month by +21.78%, over three months by +22.45% and over the past year by +88.39%.
Is BrightSpring Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BTSG is around 31.62 USD . This means that BTSG is currently undervalued and has a potential upside of +19.55% (Margin of Safety).
Is BTSG a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BTSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.4 | 11.2% |
| Analysts Target Price | 29.4 | 11.2% |
| ValueRay Target Price | 34.4 | 29.9% |
Last update: 2025-09-12 12:41
BTSG Fundamental Data Overview
CCE Cash And Equivalents = 70.1m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 111.96
P/E Forward = 25.0
P/S = 0.3945
P/B = 2.8439
Beta = None
Revenue TTM = 11.99b USD
EBIT TTM = 235.2m USD
EBITDA TTM = 424.7m USD
Long Term Debt = 2.48b USD (from longTermDebt, last quarter)
Short Term Debt = 93.2m USD (from shortTermDebt, last quarter)
Debt = 2.57b USD (Calculated: Short Term 93.2m + Long Term 2.48b)
Net Debt = 2.64b USD (from netDebt column, last quarter)
Enterprise Value = 7.46b USD (4.96b + Debt 2.57b - CCE 70.1m)
Interest Coverage Ratio = 1.23 (Ebit TTM 235.2m / Interest Expense TTM 191.5m)
FCF Yield = 2.56% (FCF TTM 191.1m / Enterprise Value 7.46b)
FCF Margin = 1.59% (FCF TTM 191.1m / Revenue TTM 11.99b)
Net Margin = 0.55% (Net Income TTM 65.5m / Revenue TTM 11.99b)
Gross Margin = 12.88% ((Revenue TTM 11.99b - Cost of Revenue TTM 10.44b) / Revenue TTM)
Tobins Q-Ratio = -44.68 (set to none) (Enterprise Value 7.46b / Book Value Of Equity -167.0m)
Interest Expense / Debt = 1.51% (Interest Expense 38.8m / Debt 2.57b)
Taxrate = 12.66% (1.24m / 9.78m)
NOPAT = 205.4m (EBIT 235.2m * (1 - 12.66%))
Current Ratio = 1.76 (Total Current Assets 2.65b / Total Current Liabilities 1.51b)
Debt / Equity = 1.48 (Debt 2.57b / last Quarter total Stockholder Equity 1.74b)
Debt / EBITDA = 6.05 (Net Debt 2.64b / EBITDA 424.7m)
Debt / FCF = 13.45 (Debt 2.57b / FCF TTM 191.1m)
Total Stockholder Equity = 1.67b (last 4 quarters mean)
RoA = 1.10% (Net Income 65.5m, Total Assets 5.94b )
RoE = 3.92% (Net Income TTM 65.5m / Total Stockholder Equity 1.67b)
RoCE = 5.67% (Ebit 235.2m / (Equity 1.67b + L.T.Debt 2.48b))
RoIC = 4.83% (NOPAT 205.4m / Invested Capital 4.26b)
WACC = 5.92% (E(4.96b)/V(7.53b) * Re(8.31%)) + (D(2.57b)/V(7.53b) * Rd(1.51%) * (1-Tc(0.13)))
Shares Correlation 3-Years: 78.90 | Cagr: 2.15%
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 69.27% ; FCFE base≈169.6m ; Y1≈111.3m ; Y5≈50.9m
Fair Price DCF = 5.40 (DCF Value 956.5m / Shares Outstanding 177.1m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 96.72 | Revenue CAGR: 18.33%
Rev Growth-of-Growth: 3.41
EPS Correlation: 53.67 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 101.8
Additional Sources for BTSG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle